Aid in dying wins approval if patient gives lethal dose

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 1
Volume 18
Issue 1

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

Oncology News International readers are on the whole in favor of “aid in dying” for terminally ill patients, but diff er on how it should be carried out.

In 2008, Washington state passed an initiative that allows doctors to prescribe lethal prescriptions to terminally ill patients who have six months or less to live. The physician must also recommend, but not require, the patient to notify next of kin. The initiative is similar to Oregon’s 1998 Death With Dignity Act.

Of those who responded to the December poll question (“Do you agree with physician-assisted suicide?”), 24% said yes, if physicians determine survival time is less than six months.

Another 24% said yes, if the patient self administers the lethal dose of medication. Finally, 16% voted in favor of having the physician administer the lethal dose.

On the other hand, 16% said no because physician-assisted suicide validates euthanasia while another 16% voted no, not under any circumstances.

See page 2 and visit www.cancernetwork.com to register your vote on this month’s question, “Considering what we know now, should ESAs ever have been approved for chemotherapy-induced anemia?”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content